Shuhang Liang

机构：University of Science and Technology of China, Anhui Provincial Hospital

发表论文 12 篇 · 总被引 987 次 · h-index 9

代表论文

• Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy (2023 · Journal of Hepatology · 被引 716)
• Donafenib and GSK‐J4 Synergistically Induce Ferroptosis in Liver Cancer by Upregulating HMOX1 Expression (2023 · Advanced Science · 被引 128)
• Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition (2023 · Frontiers in Immunology · 被引 39)
• Cytochrome B5 type A alleviates HCC metastasis via regulating STOML2 related autophagy and promoting sensitivity to ruxolitinib (2022 · Cell Death and Disease · 被引 25)
• LncRNA PWRN1 inhibits the progression of hepatocellular carcinoma by activating PKM2 activity (2024 · Cancer Letters · 被引 24)
• Acetylation-dependent regulation of core spliceosome modulates hepatocellular carcinoma cassette exons and sensitivity to PARP inhibitors (2024 · Nature Communications · 被引 16)